Alpha Bioresearch, SL

Alpha Bioresearch, SL is a company in Madrid, Spain that has taken part in 2 EU-funded projects since 2015, receiving €890k in EU funding.

EU funding received€890k
EU projects2
As coordinator0
Running now0
First EU project2015
Latest project2021
CountrySpain
EU registration (PIC)941787939
On this page · 5 sections→

Where the EU money came from

Funding by EU programme. Amounts are Alpha Bioresearch, SL's own share of each project, not the project's full budget.

  • Horizon 2020€890k · 2 projects

Projects

2 EU-funded projects, newest first. Each links to the official record.

  • A-TANGOPartner

    NOVEL TREATMENT OF ACUTE ON CHRONIC LIVER FAILURE USING SYNERGISTIC ACTION OF G-CSF AND TAK-242

    Horizon 2020 · 2021–2026 · Project on CORDIS ↗

    €291ktheir share
  • CARBALIVEPartner

    Clinical evaluation of carbons of controlled porosity as a new therapeutic for the treatment of liver cirrhosis and non-alcoholic fatty liver disease.

    Horizon 2020 · 2015–2021 · Project on CORDIS ↗

    €598ktheir share

Works most with

Organisations that shared the most EU projects with this one. A good starting list for consortium partners.

Fields it works in

Research fields recorded on its Horizon projects.

  • antibiotics
  • hepatology
  • infectious diseases
  • mortality
  • obesity
  • productivity

Is this your organisation?

Claim it with an EUACC listing (€39 once, reviewed by our editors): add what you build, your team and what you are looking for. We pre-fill it from your EU records. Listed companies reach investors through our newsletter and get matched to new EU calls first.

Claim this profile →

Source: CORDIS (Horizon Europe, Horizon 2020, FP7) and the EU Funding & Tenders Portal (other EU programmes), matched by the EU registration number (PIC). Past participation does not mean the organisation is open to new partnerships.

Europe’s tech funding.
One place.

The weekly briefing

Funding calls, VC news and key deadlines — a weekly briefing for European founders.

Free · unsubscribe anytime